← Back to Search

LY3871801 (Part B) for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose on day 1 up to postdose on day 17
Awards & highlights

Summary

This trial aims to assess the safety and tolerability of a drug (LY3871801) in healthy Asian and Non-Asian participants. It also looks at how the body processes the drug.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose on day 1 up to postdose on day 17
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose on day 1 up to postdose on day 17 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary outcome measures
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3871801
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3871801

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3871801 (Part B)Experimental Treatment1 Intervention
LY3871801 administered orally in Chinese Participants.
Group II: LY3871801 (Part A)Experimental Treatment1 Intervention
LY3871801 administered orally in Japanese and Non-Asian Participants.
Group III: Placebo (Part B)Placebo Group1 Intervention
Placebo administered orally in Chinese Participants.
Group IV: Placebo (Part A)Placebo Group1 Intervention
Placebo administered orally in Japanese and Non-Asian Participants.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3871801
2022
Completed Phase 1
~90

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,629 Previous Clinical Trials
3,218,078 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,351 Previous Clinical Trials
416,444 Total Patients Enrolled

Media Library

LY3871801 (Part B) Clinical Trial Eligibility Overview. Trial Name: NCT05960851 — Phase 1
~17 spots leftby Jul 2025